For example, HDAC2 is recruited to the promoter of p53-dependent target genes as a co-repressor to inhibit their transcription, and HDAC inhibitors can reverse the resistance of antiestrogen therapies in breast cancer [48,49]. This evidence concerns the gene HDAC9 and breast cancer.